Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021

 Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021

Shots:

  • The company reported the 1yrs. results from the P-III KESTREL & KITE studies assessing Beovu (6mg) vs aflibercept (2mg) in 926 patients with DME across 36 countries
  • Results: met its 1EPs i.e. non-inferiority in mean change BCVA from baseline @48wks., patients treated with Beovu (6mg) experienced fluid (IRF/SRF) resolution and achieved CSFT levels below 280 μm @32 & 52 wks., was well-tolerated safety in both studies
  • Novartis is committed to bring Beovu (6mg) to DME patients and will submit the data from both trails to global health authorities in H1’21 while the company anticipates 2yrs. results in late 2021

Click here to­ read full press release/ article | Ref: PRnewswire | Image: Novartis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post